Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Next Previous
Trial Profile

Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

  • 16 Apr 2025 Results assessing the he effectiveness and safety of combining anlotinib with gemcitabine and cisplatin as a first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in patients who have not received prior treatment were published in the International Journal of Cancer
  • 04 Jun 2019 According to a trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology, from August 2018, 58 patients have been enrolled in this trial.
  • 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top